Tag Archives: IOVA

Iovance Biotherapeutics Inc Gets a Buy Rating from B.Riley FBR

B.Riley FBR analyst Madhu Kumar reiterated a Buy rating on Iovance Biotherapeutics Inc (NASDAQ: IOVA) today and set a price target of $18. The company’s shares closed on Friday at $8.05, close to its 52-week high of $8.60. Kumar observed:

Iovance Biotherapeutics Inc Receives a Buy from B.Riley FBR

B.Riley FBR analyst Madhu Kumar assigned a Buy rating to Iovance Biotherapeutics Inc (NASDAQ: IOVA) today and set a price target of $18. The company’s shares closed yesterday at $7.23. Kumar wrote: “This morning, Iovance Biotherapeutics (Buy, $18.00) announced new

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics Inc (NASDAQ: IOVA) and Horizon Pharma Inc (NASDAQ: HZNP)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Iovance Biotherapeutics Inc (NASDAQ: IOVA) and Horizon Pharma Inc (NASDAQ: HZNP) with bullish sentiments. Iovance Biotherapeutics Inc (NASDAQ: IOVA) In a report

Analysts Conflicted on These Healthcare Names: Iovance Biotherapeutics Inc (NASDAQ: IOVA), Boston Scientific Corp (NYSE: BSX) and BioMarin (NASDAQ: BMRN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Iovance Biotherapeutics Inc (NASDAQ: IOVA), Boston Scientific Corp (NYSE: BSX) and BioMarin (NASDAQ: BMRN). Iovance Biotherapeutics Inc (NASDAQ: IOVA) In a report issued on October

Oppenheimer Releases a Buy Rating on Iovance Biotherapeutics Inc

In a report released today, Mark Breidenbach from Oppenheimer assigned a Buy rating to Iovance Biotherapeutics Inc (NASDAQ: IOVA), with a price target of $13. The company’s shares closed yesterday at $7.45. Breidenbach commented: “Late-breaking abstract titles for this year’s

Iovance Biotherapeutics Inc Received its Third Buy in a Row

After H.C. Wainwright and Jefferies assigned a Buy rating to Iovance Biotherapeutics Inc in the last month, the company received another Buy, this time from Oppenheimer. Analyst Mark Breidenbach reiterated a Buy rating on Iovance Biotherapeutics Inc (NASDAQ: IOVA) today